RxDoctor Payments Data

Chirag Mehta, MD

Cardiovascular Disease · Victorville, CANPI 1144483256

Payments from drug & device makers

$34,943in general payments, 2019–2025

Across 601 payments — averaging $58.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$20K
  • Cardiovascular Systems Inc.$2K
  • Angiodynamics, Inc.$2K
  • Boston Scientific$2K
  • Novartis$987
  • AstraZeneca$911
  • plus $8K from 40 others

What the payments were for

  • Consulting fees$10,00029%
  • Speaking & faculty fees$8,10023%
  • Travel & lodging$3,3169%
  • Food & beverage$13,49739%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,943 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,482,237
Medicare patients
630
Services billed
5,765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$147,446
EntrestoSacubitril/Valsartan80$70,098
XareltoRivaroxaban64$50,136
BrilintaTicagrelor35$31,659
FarxigaDapagliflozin Propanediol48$29,812
JardianceEmpagliflozin27$23,220
MultaqDronedarone Hcl11$20,921
DapagliflozinDapagliflozin Propanediol24$15,920
Repatha SureclickEvolocumab17$9,067
Metoprolol Succinate160$1,548
ClopidogrelClopidogrel Bisulfate159$1,490
Ranolazine ErRanolazine21$1,175
Atorvastatin Calcium133$963
Isosorbide Dinitrate14$743
Amiodarone Hcl57$707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$490$147,446174 claims
NovartisEntresto$987$70,09880 claims
AstraZenecaBrilinta, Farxiga$911$61,47183 claims
Johnson & JohnsonXarelto$332$50,13664 claims
Boehringer IngelheimJardiance$267$23,22027 claims
Sanofi-aventis U.S. LLCMultaq$668$20,92111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Victorville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →